Zofer 2mg/ml Injection contains Ondansetron, a selective 5-HT3 receptor antagonist used primarily for the prevention and treatment of nausea and vomiting associated with chemotherapy, radiotherapy, and postoperative recovery. Ondansetron works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting, at the 5-HT3 receptors located centrally in the chemoreceptor trigger zone and peripherally in the gastrointestinal tract. Zofer 2mg/ml Injection is indicated for use in adult and pediatric patients requiring rapid and effective control of emesis. The injection is administered intravenously or intramuscularly, allowing for prompt onset of action, which is critical in acute settings such as chemotherapy-induced nausea or postoperative nausea and vomiting. Dosage should be individualized based on patient condition, treatment regimen, and clinical response, with careful consideration of hepatic function due to Ondansetron’s metabolism in the liver. Common adverse effects include headache, constipation, and dizziness, while serious side effects are rare but may include hypersensitivity reactions and QT interval prolongation. Zofer 2mg/ml Injection should be used under medical supervision, with monitoring for efficacy and potential side effects to ensure optimal patient outcomes.